Semaglutide [2], a glucagon-like peptide-1 receptor agonist (GLP-1RA), is the first of these new agents to obtain regulatory approval for the treatment of obesity, with tirzepatide [3] and other drugs [4] showing even stronger potential. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.